A Review of Von Hippel-Lindau Syndrome

Main Article Content

Neha Varshney
Amanuel A. Kebede
Harry Owusu-Dapaah
Jason Lather
Manu Kaushik
Jasneet S. Bhullar


endolymphatic sac tumors, emangioblastomas, pancreatic neuroendocrine tumors, pheochromocytoma, von Hippel-Lindausyndrome


Von Hippel-Lindau syndrome (VHL) is a familial neoplastic condition seen in approximately 1 in 36,000 live births. It is caused by germline mutations of the tumor suppressor gene VHL, located on the short arm of chromosome 3. While the majority of the affected individuals have a positive family history, up to 20% of cases arise from de novo mutations. VHL syndrome is characterized by the presence of benign and malignant tumors affecting the central nervous system, kidneys, adrenals, pancreas, and reproductive organs. Common manifestations include hemangioblastomas of the brain, spinal cord, and retina; pheochromocytoma and paraganglioma; renal cell carcinoma; pancreatic cysts and neuroendocrine tumors; and endolymphatic sac tumors. Diagnosis of VHL is prompted by clinical suspicion and confirmed by molecular testing. Management of VHL patients is complex and multidisciplinary. Routine genetic testing and surveillance using various diagnostic techniques are used to help monitor disease progression and implement treatment options. Despite recent advances in clinical diagnosis and management, life expectancy for VHL patients remains low at 40–52 years. This article provides an overview of the major clinical, histological, and radiological findings, as well as treatment modalities.

Abstract 5335 | PDF Downloads 2702 HTML Downloads 3830 XML Downloads 673


1. Maher ER. Von Hippel-Lindau disease. Eur J Can. 1994 Jan;30(13):1987–90. http://dx.doi.org/10.1016/0959-8049(94)00391-H
2. Poulsen ML, Budtz-Jørgensen E, Bisgaard ML. Surveillance in von Hippel-Lindau disease (VHL). Clin Genet. 2010 Jan;77(1):49–59. http://dx.doi.org/10.1111/j.1399-0004.2009.01281.x
3. Wilding A, Ingham SL, Lalloo F, Clancy T, Huson SM, Moran A, et al. Life expectancy in hereditary cancer predisposing diseases: An observational study. J Med Genet. 2012 Apr;49(4):264–9. http://dx.doi.org/10.1136/jmedgenet-2011-100562
4. Iliopoulos O, Ohh M, Kaelin WG. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci U S A. 1998;95:11661–6. http://dx.doi.org/10.1073/pnas.95.20.11661
5. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, et al. Von Hippel-Lindau disease. Lancet. 2003 Jun; 361(9374):2059–67. http://dx.doi.org/10.1016/S0140-6736(03)13643-4
6. Maher ER, Neumann HP, Richard S. von Hippel–Lindau disease: A clinical and scientific review. Eur J Hum Genet. 2011 Jun;19(6):617–23. http://dx.doi.org/10.1038/ejhg.2010.175
7. Singh AD, Shields CL, Shields JA. Von Hippel–Lindau disease. Surv Ophthalmol. 2001 Oct;46(2):117–42. http://dx.doi.org/10.1016/S0039-6257(01)00245-4
8. Richard S, Graff J, Lindau J, Resche F. von Hippel-Lindau disease. Lancet. 2004 Apr;363(9416):1231–4. http://dx.doi.org/10.1016/S0140-6736(04)15957-6
9. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999 May;399(6733):271–5. http://dx.doi.org/10.1038/20459
10. Kaelin WG Jr. The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer. 2008 Nov;8(11):865–73. http://dx.doi.org/10.1038/nrc2502
11. Ong KR, Woodward ER, Kellick P, Lim C, Macdonald F, Maher ER. Genotype–phenotype correlations in von Hippel-Lindau disease. Hum Mutat. 2007 Feb; 28(2):143–9. http://dx.doi.org/10.1002/humu.20385
12. O’Brien FJ, Danapal M, Jairam S, Lalani AK, Cunningham J, Morrin M, et al. Manifestations of Von Hippel Lindau syndrome: A retrospective national review. QJM. 2014 Apr;107(4):291–6. http://dx.doi.org/10.1093/qjmed/hct249
13. Cassol C, Mete O. Endocrine manifestations of von Hippel-Lindau disease. Arch Pathol Lab Med. 2015 Feb;139(2):263–8. http://dx.doi.org/10.5858/arpa.2013-0520-RS
14. Chittiboina P, Lonser RR. Von Hippel–Lindau disease. Handb Clin Neurol. 2015;132:139–56. http://dx.doi.org/10.1016/B978-0-444-62702-5.00010-X
15. Wind JJ, Lonser RR. Management of von Hippel-Lindau disease-associated CNS lesions. Expert Rev Neurother. 2011 Oct;11(10):1433. http://dx.doi.org/10.1586/ern.11.124
16. Shanbhogue KP, Hoch M, Fatterpaker G, Chandarana H. Von Hippel-Lindau Disease: Review of genetics and imaging. Radiol Clin North Am. 2016 May;54(3):409–22. http://dx.doi.org/10.1016/j.rcl.2015.12.004
17. Lonser RR, Butman JA, Huntoon K, Asthagiri AR, Wu T, Bakhtian KD, et al. Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease: Clinical article. J Neurosurg. 2014 May;120(5):1055–62. http://dx.doi.org/10.3171/2014.1.JNS131431
18. Butman JA, Linehan WM, Lonser RR. Neurologic manifestations of von Hippel-Lindau disease. JAMA. 2008 Sep;300(11):1334–42. http://dx.doi.org/10.1001/jama.300.11.1334
19. Frantzen C, Klasson TD, Links TP, Giles RH. Von Hippel-Lindau syndrome. GeneReviews. 2015 Aug. PMID 20301636.
20. Asthagiri AR, Mehta GU, Zach L, Li X, Butman JA, Camphausen KA, et al. Prospective evaluation of radiosurgery for hemangioblastomas in von Hippel–Lindau disease. Neuro Oncol. 2010 Jan;12(1):80–6. http://dx.doi.org/10.1093/neuonc/nop018
21. Kim HJ, Hagan M, Butman JA, Baggenstos M, Brewer C, Zalewski C, et al. Surgical resection of endolymphatic sac tumors in von Hippel-Lindau disease: Findings, results, and indications. Laryngoscope. 2013 Feb;123(2):477–83. http://dx.doi.org/10.1002/lary.23646
22. Ashouri K, Mohseni S, Tourtelot J, Sharma P, Spiess PE. Implications of Von Hippel-Lindau syndrome and renal cell carcinoma. J Kidney Cancer VHL. 2015 Sep;2(4):163–73. http://dx.doi.org/10.15586/jkcvhl.2015.41
23. Young EE, Castle SM, Gorbatiy V, Leveillee RJ. Comparison of safety, renal function outcomes and efficacy of laparoscopic and percutaneous radio frequency ablation of renal masses. J Urol. 2012 Apr;187(4):1177–82. http://dx.doi.org/10.1016/j.juro.2011.11.099
24. Benhammou JN, Boris RS, Pacak K, Pinto PA, Linehan WM, Bratslavsky G. Functional and oncologic outcomes of partial adrenalectomy for pheochromocytoma in patients with von Hippel-Lindau syndrome after at least 5 years of followup. J Urol. 2010 Nov;184(5):1855–9. http://dx.doi.org/10.1016/j.juro.2010.06.102
25. Blansfield JA, Choyke L, Morita SY, Choyke PL, Pingpank JF, Alexander HR, et al. Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine tumors (PNETs). Surgery. 2007 Dec;142(6):814–18. http://dx.doi.org/10.1016/j.surg.2007.09.012
26. Simpson JL, Carson SA, Cisneros P. Preimplantation genetic diagnosis (PGD) for heritable neoplasia. J Natl Cancer Inst Monogr. 2005 Mar;34:87–90. http://dx.doi.org/10.1093/jncimonographs/lgi027